🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04295473
Recruiting Not applicable

Reduced Port Laparoscopic Gastrectomy for Gastric Cancer

NCT04295473 · tracked via the Priya Life Science China tracker
Sponsor
Nanchong Central Hospital
Phase
Not applicable
Started
2020-03-02
Last updated
2025-05-21

Condition(s) studied

LaparoscopicGastrectomy

Investigational drug(s) / intervention(s)

Reduced port laparoscopic gastrectomy

Reduced port laparoscopic gastrectomy: The ports were reduced in the surgery of intervention arm.

Study summary

Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The investigators sought to compare the short and long-term outcome of patients with gastric cancer who underwent reduced port gastrectomy with patients underwent traditional laparoscopic gastrectomy

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Adequate organ function. Exclusion Criteria: 1. Patients had distant metastasis. 2. oesophageal invasion of more than 3 cm. 3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma. 4. Previous chemotherapy or radiation therapy for any other malignancies.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yunhong Tian Nanchong Sichuan Recruiting

More Nanchong Central Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04295473 on ClinicalTrials.gov ↗ ← All trials in China